| [January 27, 2005] |
 |
VisiJet CEO Randy Bailey Interviewed by Television Stations Nationwide About New, Safer Method of Laser Eye Surgery
NEW YORK --(Business Wire)-- Jan. 27, 2005 -- Randy Bailey, CEO of VisiJet, Inc. (OTC BB: VJET) was interviewed by television stations across the country today concerning the efficacy of various methods of corrective vision surgery and the Company's lead product, the EpiLift System, that enables a safer, superior method of surgery - Epi-LASIK.
Television stations that interviewed Bailey included KFTY San Francisco, KTVO St. Louis, MO and WFLA Tampa, FL, among others.
During the interviews, Bailey discussed the differences between various methods of corrective vision surgery and how Epi-LASIK offers a viable alternative to people considering the procedure who are concerned about the risks associated with traditional LASIK.
Anyone interested in receiving a CD of aired interviews may submit a request to afaville@investorrelationsgroup.com or mgraff@investorrelationsgroup.com.
About VisiJet
VisiJet, Inc. is a medical device company based in Irvine, California focused on the development and marketing of innovative ophthalmic applications. The company recently received FDA approval for its EpiLift system, a next-generation, ophthalmic surgical device designed for separating corneal tissue. The EpiLift system is the cornerstone of a new improvement in Lasik surgery called Epi-LASIK. The EpiLift systems improve upon existing technologies with unique separating methods that can eliminate many postoperative problems. The EpiLift system is manufactured by Gebauer Medizintechnik GmbH.
In addition to the EpiLift system, VisiJet is developing HydroKeratome(R) and Pulsatome(R), which utilize the company's proprietary and patented waterjet technology. These products result in faster, safer and more efficacious procedures in two of the largest surgical markets in the world: refractive and cataract surgeries. HydroKeratome(R) uses the waterjet technology, employing a high-pressure micro beam of water with the diameter of a human hair to cut the corneal flap as required in LASIK surgery. The Pulsatome(R) cataract emulsifier, currently under development, is a device that uses pulsed waterjet technology to remove cataracts - the most frequently performed surgical procedure in the world.
This release contains forward-looking statements that reflect the company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company's quarterly, annual and other regular filings.
[ Back To TMCnet.com's Homepage ]
|
TMCnet LOGIN
Webinars
